Kyntra Bio faces Nasdaq delisting after failing to meet Listing Rule 5450(b) requirements

KYNB•2026-10-06

Nasdaq staff moved to delist Kyntra Bio after it missed Listing Rule 5450(b) requirements by a Sept. 29, 2026, deadline. A timely hearing request stays any suspension while a panel considers the case; shares continue trading as KYNB.

1. Delisting determination

Nasdaq staff moved to delist Kyntra Bio shares from the Nasdaq Global Select Market in a determination letter dated Sept. 30, 2026, citing the company’s failure to meet the Sept. 29 compliance deadline. The company filed a hearing request on time, staying any suspension, and its shares continue trading as KYNB pending a panel decision. The panel may grant an extension of up to 180 days from the determination. An April 2, 2026, notice had flagged failure to meet the $50 million total assets and total revenue thresholds.

Sources

Kyntra Bio faces Nasdaq delisting after failing to meet Listing Rule 5450(b) requirements

Sec

Kyntra Bio faces Nasdaq delisting after failing to meet Listing Rule 5450(b) requirements

1. Delisting determination

Related News

NextEra Energy to adopt governance reforms for at least four years

Flowserve CFO Brian William Ezzell files initial beneficial ownership statement

USCB Financial sets third-quarter results release and earnings call

Sources

Kyntra Bio faces Nasdaq delisting after failing to meet Listing Rule 5450(b) requirements

TWG announces receipt of Nasdaq minimum bid price notification

BeyondSpring sells BeyondSpring Ltd stake to Hong Kong investor in data-for-funding deal